BioSpace News Archive

ITM Isotope Technologies Munich SE announced that it will host a multidisciplinary symposium titled, “Investing in the Future of Theranostics: Aligning Supply to Clinical Need,” at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference, held from June 24-27 in Chicago, Illinois, USA.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023.

Vera Therapeutics, Inc. announced it will host a post-ERA data presentation on Tuesday, June 20, 2023 at 8:00 AM ET.

NeoGenomics, Inc. announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California.

Clene Inc., along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock.

Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces that it received the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023.

Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Everest Medicines announced that Dr. Mike Berry has been appointed Chief Technology Officer, effective immediately.

HUTCHMED Limited and Takeda announced that results of the Phase III FRESCO-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer were published in The Lancet.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Columvi® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.